Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FCOB04
- Development stage
- Phase 1
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-FCOB04 is a fluorine-18 labeled radiopharmaceutical developed by Peking Union Medical College Hospital for use as a positron emission tomography (PET) imaging agent. It selectively targets monoamine oxidase B (MAO-B), an enzyme primarily located in the outer mitochondrial membrane of astrocytes. In neurodegenerative diseases, MAO-B expression is significantly upregulated due to reactive astrogliosis, a key pathological feature of neuroinflammation. By binding to MAO-B, 18F-FCOB04 allows for the non-invasive visualization and quantification of astrogliosis using PET imaging, serving as a diagnostic tool and biomarker for disease progression in conditions such as Alzheimer's disease and Parkinson's disease. It is currently being evaluated in early-phase clinical trials to assess its safety, biodistribution, and diagnostic utility.
- Other names
- [18F]FCOB04
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on 18F-FCOB04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FCOB04.